Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY900014 in Participants With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Are male or female participants with Type 2 Diabetes Mellitus (T2DM) for at least 1 year~* Have a body mass index (BMI) of 18.5 to 35.0 kilogram per meter square (kg/m²)~* Have a glycated hemoglobin (HbA1c) less than (\<)9.0 percent (%)~* Have had no episodes of severe hypoglycaemia in the last 6 months~Exclusion Criteria:~* Have a history or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine (apart from T2DM), hematological, or neurological disorders capable of significantly altering the absorption, metabolism or elimination of drugs; of constituting a risk when taking the investigational product; or of interfering with the interpretation of data~* Have a history of renal impairment~* Have a history of deep vein thrombosis of the leg or repeated episodes of deep leg vein thrombosis in first-degree relatives~* Have proliferative retinopathy or maculopathy and/or severe neuropathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- LY900014 (Type: EXPERIMENTAL): Single, subcutaneous (SC) dose of 15 Units (U) LY900014 in one of two study periods
- Insulin Lispro (Humalog) (Type: ACTIVE_COMPARATOR): Single SC dose of 15 U insulin lispro (Humalog) in one of two study periods

Based on this trial design, predict the completion outcome and termination type (if applicable).